Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Elena S. Koltun, Mallika Singh et al.|Nature|2024Cited by 319
Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Cancer Research|2022Cited by 160
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E. Klomp, Clint A. Stalnecker|Science|2024Cited by 79
Time-Variant SRC Kinase Activation Determines Endothelial Permeability ResponseJennifer E. Klomp, Andrei V. Karginov, Mark Shaaya et al.|Cell chemical biology|2019Cited by 38
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.Mareen Lüthen, Sehrish Javaid, Jennifer E. Klomp et al.|UNC Libraries|2024Cited by 12